Related Experiment Videos
[Cholestatic jaundice during lovastatin medication]
U Spreckelsen1, R Kirchhoff, H Haacke
1Innere Abteilung, Kreiskrankenhauses Husum.
Insights
Lovastatin, a cholesterol-lowering drug, can rarely cause cholestatic jaundice in patients with hyperlipoproteinaemia. Discontinuation of the drug led to the resolution of jaundice, suggesting a direct effect.
Area of Science:
- Pharmacology
- Hepatology
- Clinical Medicine
Background:
- Type IIb hyperlipoproteinaemia is a condition characterized by elevated cholesterol and triglycerides.
- Dietary management alone was insufficient for this patient's condition.
- Lovastatin is an HMG-CoA reductase inhibitor used to lower lipid levels.
Observation:
- A patient with type IIb hyperlipoproteinaemia developed cholestatic jaundice after two months of lovastatin treatment.
- Biochemical markers indicated significant liver dysfunction, specifically elevated bilirubin.
- Symptoms and biochemical abnormalities resolved within two weeks of discontinuing lovastatin.
Findings:
- The case suggests lovastatin can induce cholestatic jaundice, a rare side effect.
- Hepatocellular damage is a known side effect, but cholestasis is less common.
- Exclusion of other causes strengthens the link between lovastatin and jaundice.
Implications:
- Clinicians should be aware of the potential for lovastatin-induced cholestasis.
- Monitoring liver function is crucial during statin therapy.
- This case highlights the need for vigilance regarding rare adverse drug reactions.
Abstract:
A 48-year-old man had type IIb hyperlipoproteinaemia which could not be satisfactorily treated with diet alone (total cholesterol 351 mg/dl, HDL cholesterol 36 mg/dl, triglycerides 480 mg/dl). Treatment with lovastatin (an HMG-CoA reductase inhibitor) was then started at a dosage of 20 mg daily. After two months on the drug cholestatic jaundice developed (total bilirubin 6.15 mg/dl). The jaundice and abnormal biochemical findings regressed within two weeks of discontinuing lovastatin. All other possible causes of jaundice were excluded. These observations indicate that, in addition to hepatocellular damage, lovastatin may in rare instances also exert a cholestatic effect.